U.S. Markets open in 5 mins
  • S&P Futures

    3,318.00
    -65.00 (-1.92%)
     
  • Dow Futures

    26,752.00
    -613.00 (-2.24%)
     
  • Nasdaq Futures

    11,402.75
    -185.25 (-1.60%)
     
  • Russell 2000 Futures

    1,552.40
    -36.60 (-2.30%)
     
  • Crude Oil

    37.39
    -2.18 (-5.51%)
     
  • Gold

    1,879.60
    -32.30 (-1.69%)
     
  • Silver

    23.51
    -1.06 (-4.31%)
     
  • EUR/USD

    1.1732
    -0.0058 (-0.4927%)
     
  • 10-Yr Bond

    0.7510
    -0.0270 (-3.47%)
     
  • Vix

    37.84
    +5.38 (+16.57%)
     
  • GBP/USD

    1.2947
    -0.0094 (-0.7224%)
     
  • USD/JPY

    104.3430
    -0.1510 (-0.1445%)
     
  • BTC-USD

    13,271.83
    -438.19 (-3.20%)
     
  • CMC Crypto 200

    262.75
    +1.46 (+0.56%)
     
  • FTSE 100

    5,601.27
    -127.72 (-2.23%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Novo Nordisk Completes Two Studies on Obesity Candidate

Zacks Equity Research
·2 mins read

Novo Nordisk A/S NVO announced headline results from two studies — a once-weekly subcutaneous amylin analogue or AM833 (as monotherapy) and a combination study of AM833 and once-weekly subcutaneous semaglutide 2.4 mg.

AM833 is an acylated long-acting analogue of the human amylin hormone that induces weight loss by reducing energy intake.

In the phase II monotherapy study,safety, tolerability and efficacy of AM833 wereinvestigated for weight management in 706 people with obesity or overweight with at least one weight-related comorbidity. The study reached its primary endpoint by demonstrating a weight loss of 10.8% at week 26 with AM833 at the 4.5 mg dose compared to a weight loss of 3.0 % with placebo.

The 20-week multiple ascending dose phase I study evaluated the weight loss potential of AM833 administrated in combination with semaglutide 2.4 mg in 80 people with obesity or overweight. Once-weekly subcutaneous semaglutide 2.4 mg is being investigated by Novo Nordisk as a treatment for adults with obesity.

After 20 weeks of treatment, participants receiving the highest dose lost 17.1% of body weight, on average, from a mean baseline body weight of 95.1 kg. The primary endpoint was the number of treatment-emergent adverse events and AM833 was well-tolerated, with the most common adverse events being gastrointestinal disorders, including nausea and vomiting, the majority being non-serious and mild or moderate in severity.

Shares of the company have gained 16.7% year to date against the industry’s decline of 1.8%.

Novo Nordisk has a strong presence in the diabetes care market with one of the broadest diabetes portfolios in the industry. However, the diabetes market is extremely crowded with players like Sanofi SNY, AstraZeneca AZN and Merck MRK.

 

Novo Nordisk AS Price

 

Novo Nordisk AS Price
Novo Nordisk AS Price

Novo Nordisk AS price | Novo Nordisk AS Quote

Zacks Rank

Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020? Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novo Nordisk AS (NVO) : Free Stock Analysis Report
 
Sanofi (SNY) : Free Stock Analysis Report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
Merck Co., Inc. (MRK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research